Dapagliflozin associated ketoacidosis: A must know fact for nephrologists

E-ISSN： 1440-1797|23|2|192-192

ISSN： 1320-5358

Source： NEPHROLOGY, Vol.23, Iss.2, 2018-02, pp. : 192-192

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Climate change and us: What nephrologists should know

NEPHROLOGY, Vol. 20, Iss. 10, 2015-10 ,pp. : 760-764

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiac Assist Devices and Hemodialysis Catheter Procedures – What Do the Nephrologists Need to Know?

SEMINARS IN DIALYSIS, Vol. 28, Iss. 6, 2015-11 ,pp. : 670-675

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in ANCA-Associated Vasculitis: Fad or Fact?

Nephron Clin Pract, Vol. 118, Iss. 2, 2010-12 ,pp. : c182-c188

Karger

Access to resources Recommend Favorite

Doctor Does Not Know Best: Why in the New Century Physicians Must Stop Trying to Benefit Patients

By Veatch Robert M.

The Journal of Medicine and Philosophy, Vol. 25, Iss. 6, 2000-12 ,pp. : 701-721

Oxford University Press

Access to resources Recommend Favorite

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 344-351

John Wiley & Sons Inc

Access to resources Recommend Favorite